Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment

J Cyst Fibros. 2017 Mar;16(2):222-229. doi: 10.1016/j.jcf.2016.08.005. Epub 2016 Sep 17.

Abstract

Background: The influence of suppressive therapy on the different P. aeruginosa phenotypes harbored in the lungs of cystic fibrosis (CF) patients remains unclear. Our aim was to investigate the phenotypic changes (mucoidy, hypermutability, antibiotic resistance, transcriptomic profiles and biofilm) in P. aeruginosa populations before and after a 2-week course of suppressive antimicrobial therapy in chronically infected CF patients in Denmark.

Material and methods: Prospective observational clinical study. Sputum samples were assessed before and after treatment for P. aeruginosa, with regard to: a) colony-forming units (CFU/mL), b) frequency of mucoids and non-mucoids, c) resistance pattern to anti-pseudomonal drugs, d) hypermutability, e) transcriptomic profiles, and f) presence of biofilms.

Results: We collected 23 sputum samples (12 before antibiotic treatment and 11 after) and 77 P. aeruginosa from different CF patients. After treatment, the P. aeruginosa burden diminished but antimicrobial resistance to aztreonam, tobramycin and ceftazidime rose; non-mucoid phenotypes presented increased resistance to colistin, tobramycin, meropenem, and ciprofloxacin, and hypermutable phenotypes to ciprofloxacin. In spite of biofilm persistence, a down-regulation of genes involved in denitrification was detected.

Conclusion: A 2-week course of suppressive therapy reduces P. aeruginosa lung colonization and influences nitrogen metabolism genes, but also promotes antimicrobial resistance while P. aeruginosa persists in biofilms.

Keywords: Bacterial infection; Biofilm; Cystic fibrosis; Pseudomonas aeruginosa; Respiratory infection.

Publication types

  • Observational Study

MeSH terms

  • Anti-Infective Agents* / classification
  • Anti-Infective Agents* / therapeutic use
  • Biofilms / drug effects
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / epidemiology
  • Cystic Fibrosis* / microbiology
  • Denmark / epidemiology
  • Drug Resistance, Microbial
  • Gene Expression Regulation, Bacterial
  • Humans
  • Microbial Sensitivity Tests / methods
  • Pseudomonas Infections / diagnosis
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa* / genetics
  • Pseudomonas aeruginosa* / pathogenicity
  • Pseudomonas aeruginosa* / physiology
  • Respiratory Tract Infections / diagnosis
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / epidemiology
  • Respiratory Tract Infections / microbiology*
  • Sputum / microbiology

Substances

  • Anti-Infective Agents